Moving Forward in the Treatment of AML: New Findings, Improved Outcomes

Moving Forward in the Treatment of AML: New Findings, Improved Outcomes

On-Demand Webcast
FACULTY

Pinkal Desai, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York

Sangmin Lee, MD
Assistant Professor
Weill Cornell Medicine
New York, New York

Alexander Perl, MD
Associate Professor, Perelman School of Medicine Leukemia Program
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Ellen K. Ritchie, MD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
New York, New York

Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program
Weill Cornell Medicine
New York, New York

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This educational activity is specifically designed for hematologists/oncologists, physician assistants, nurse practitioners, nurses, and pharmacists who specialize in hematology, as well as other healthcare providers who care for patients with hematologic malignancies.

OVERVIEW

In past decades, chemotherapy was the only available treatment for acute myeloid leukemia (AML). While survival improved in younger patients during this period, this was credited to better supportive care and improved hematopoietic stem cell transplantation techniques rather than an improvement in pharmacotherapies. Today, with a better understanding of the genetic and molecular underpinnings of the disease, and with the consequent advent of several targeted therapies, treatment has made remarkable progress in extending life and sometimes offering a cure for these patients. However, the treatment of AML continues to challenge clinicians—while the number of treatment options can be daunting, which is in itself a challenge, AML for some patients remains uncurable. Clinicians encounter many treatment barriers in AML, especially among high-risk patient populations, such as the elderly, patients not eligible for intensive chemotherapy, and those with relapsed or refractory (R/R) disease. The need for effective and safe treatment alternatives to traditional therapy for these patient populations is urgent. Fortunately, recent and rapid changes in the AML treatment landscape have been made, but such advances require education on new clinical data and expert guidance to facilitate the clinical integration of these changes. 

This webcast aims to fill the gaps surrounding the latest evidence regarding the efficacy and safety profiles of recently approved therapies, emerging data from ongoing trials, and practical approaches to incorporating these therapies into clinical practice for the treatment of patients with AML.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

  • Review pharmacotherapeutic advances for the management of AML, including mechanism of action, safety, and efficacy  
  • Outline patient factors, such as age and disease status, that impact management decisions 
  • Discuss the clinical value of performing full karyotyping and genetic analyses in patients with AML 
  • Incorporate newer chemotherapeutic formulations and targeted therapy for patient-centric treatment of AML 
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: November 16, 2020
Expiration Date: November 16, 2021
Estimated Time to Complete: 1.5 hours

There is no fee associated with this activity.

COMMERCIAL SUPPORT

Supported by educational grants from: Astellas Pharma and Jazz Pharmaceuticals.

CONTINUING EDUCATION

 

In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

NACCME designates this internet enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

NURSING

This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours. 

PHARMACY

This internet enduring, knowledge-based activity (Universal Activity Number: JA0006201-0000-20-204-H01-P) has been approved for a maximum of 1.50 contact hours (.150 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Christopher Bolwell, Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Shannon Stevenson, and Griselda Zuccarino-Catania. 

Christopher Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their products or services.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

No other planner has disclosed a relevant financial relationship with any commercial interest.

Faculty

The faculty has reported the following:

Pinkal Desai: Advisory Board-BMS/Celgene

Sangmin Lee: Consultant-Acerta/AstraZeneca, BMS, Helsinn, Jazz Pharmaceuticals, Karyopharm, Pfizer

Alexander Perl: Advisory Board-AbbVie, Astellas, Daiichi Sankyo, Loxo Oncology, Syndax; Consultant-AbbVie, Actinium, Astellas, Daiichi Sankyo, Forma Therapeutics, Sumitomo Dainippon; Other Financial or Material Support-AbbVie, Astellas, Daiichi Sankyo 

Ellen Ritchie: Advisory Board-Incyte Corporation, Novartis, Pfizer; Consultant-Novartis

Gail Roboz: Consultant-AbbVie, Actinium, Agios, Amphivena, Argenyx, Array Biopharma, Astellas, Astex, AstraZeneca, Bayer, Celgene Corp., Celltrion, Daiichi Sankyo, Eisai, Epizyme, Genentech/Roche, Glaxo Smith Kline, Helsinn, Janssen Pharmaceuticals, Jasper Therapeuticals, JAZZ, Mei Pharma, Mesoblast, Novartis, Orsenix, Otsuka, Pfizer, Sandoz, Takeda, Trovagene; Grant/Research Support-Cellectis

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

GRIEVANCE POLICY

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at c.bolwell@imedex.com or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.